Kane Biotech Company Description

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.

The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.

It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.

The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection.

Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Kane Biotech Inc.

Country	Canada
Founded	2001
Industry	Biotechnology
Sector	Healthcare
CEO	Marc Edwards

Contact Details

Address: 100 Innovation Drive Winnipeg, R3T 6G2 Canada
Phone	204-453-1301
Website	kanebiotech.com

Stock Details

Ticker Symbol	KNE
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	CAD
ISIN Number	CA4838092084
SIC Code	2836

Key Executives

Name	Position
Marc Edwards	President, Chief Executive Officer and Director
Ray Dupuis	Chief Financial Officer
Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC	Executive Chairman and Member of Scientific Advisory Board
Dr. Gregory S. Schultz Ph.D.	Chief Scientific Officer and Member of Scientific Advisory Board
Lorne Gorber	Investor Relations
Wendy Nachtigall	Director of Marketing
Lori Christofalos	Chief Quality Officer
Nicole Sendey	Investor Relations Adviser